Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein

Journal of Lipid Research

Volumn 53, Issue 10, 2012, Pages 2017-2023

  Vrins, Carlos L J ^a   Ottenhoff, Roelof ^a   Van Den Oever, Karin ^a   De Waart, Dirk R ^a   Kruyt, J Kar ^b   Zhao, Ying ^b   Van Berkel, Theo J C ^b   Havekes, Louis M ^c   Aerts, Johannes M ^a   Van Eck, Miranda ^b   Rensen, Patrick C N ^c   Groen, Albert K ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apolipoproteins; Bile; Intestine; Neutral sterols; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EMULSION; HUMAN; KINETICS; LIPID ABSORPTION; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METABOLISM; TRANSINTESTINAL CHOLESTEROL EFFLUX; ULTRACENTRIFUGATION;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; INTESTINES; LIPOPROTEINS, HDL; LIVER; MALE; MICE; MICE, INBRED STRAINS; SCAVENGER RECEPTORS, CLASS B;

EID: 84866155091     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M022194     Document Type: Article

References (33)

1. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
2. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
3. Tall, A. R. 2008. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263: 256-273.
4. Rader, D. J. 2007. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat. Clin. Pract. Cardiovasc. Med. 4: 102-109.
5. van der Velde, A. E., C. L. Vrins, K. Van den Oever, C. Kunne, R. P. Oude Elferink, F. Kuipers, and A. K. Groen. 2007. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 133: 967-975.
6. Temel, R. E., J. K. Sawyer, L. Yu, C. Lord, C. Degirolamo, A. McDaniel, S. Marshall, N. Wang, R. Shah, L. L. Rudel, et al. 2010. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 12: 96-102.
7. Hussain, M. M. 2000. A proposed model for the assembly of chylomicrons. Atherosclerosis. 148: 1-15.
8. Brunham, L. R., J. K. Kruit, J. Iqbal, C. Fievet, J. M. Timmins, T. D. Pape, B. A. Coburn, N. Bissada, B. Staels, A. K. Groen, et al. 2006. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116: 1052-1062.
9. van der Velde, A. E., C. L. Vrins, K. Van den Oever, I. Seemann, R. P. Oude Elferink, M. Van Eck, F. Kuipers, and A. K. Groen. 2008. Regulation of direct transintestinal cholesterol excretion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G203-G208.
10. Hamon, Y., C. Broccardo, O. Chambenoit, M. F. Luciani, F. Toti, S. Chaslin, J. M. Freyssinet, P. F. Devaux, J. McNeish, D. Marguet, et al. 2000. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2: 399-406.
11. Rigotti, A., B. L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger. 1997. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. USA. 94: 12610-12615.
12. Zhao, Y., M. Pennings, C. L. Vrins, L. Calpe-Berdiel, M. Hoekstra, J. K. Kruijt, R. Ottenhoff, R. B. Hildebrand, R. van der Sluis, W. Jessup, et al. 2011. Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BI. Atherosclerosis. 218: 314-322.
13. Rensen, P. C., M. C. van Dijk, E. C. Havenaar, M. K. Bijsterbosch, J. K. Kruijt, and T. J. Van Berkel. 1995. Selective liver targeting of antivirals by recombinant chylomicrons-a new therapeutic approach to hepatitis B. Nat. Med. 1: 221-225.
14. Mortimer, B. C., D. J. Beveridge, I. J. Martins, and T. G. Redgrave. 1995. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J. Biol. Chem. 270: 28767-28776.
15. Fluiter, K., H. Vietsch, E. A. Biessen, G. M. Kostner, T. J. Van Berkel, and W. Sattler. 1996. Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem. J. 319: 471-476.
16. Herz, J., S. Q. Qiu, A. Oesterle, H. V. DeSilva, S. Shafi, and R. J. Havel. 1995. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 92: 4611-4615.
17. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, E. M. Van, and T. J. Van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070-1084.
18. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
19. Huang, H., J. W. Kauan, and G. G. Guilbault. 1975. Fluorometric enzymatic determination of total cholesterol in serum. Clin. Chem. 21: 1605-1608.
20. van der Veen, J. N., T. H. van Dijk, C. L. Vrins, H. Van Meer, R. Havinga, K. Bijsterveld, U. J. Tietge, A. K. Groen, and F. Kuipers. 2009. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284: 19211-19219.
21. Quarfordt, S. H., and D. S. Goodman. 1967. Metabolism of doubly-labeled chylomicron cholesteryl esters in the rat. J. Lipid Res. 8: 264-273.
22. Thomas, M. S., and L. L. Rudel. 1987. Intravascular metabolism of lipoprotein cholesteryl esters in African green monkeys: differential fate of doubly labeled cholesteryl oleate. J. Lipid Res. 28: 572-581.
23. Post, S. M., M. Groenendijk, C. C. van der Hoogt, C. Fievet, G. Luc, M. Hoekstra, H. M. Princen, B. Staels, and P. C. Rensen. 2006. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 26: 2724-2730.
24. Groen, A. K., V. W. Bloks, R. H. Bandsma, R. Ottenhoff, G. Chimini, and F. Kuipers. 2001. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J. Clin. Invest. 108: 843-850.
25. Brown, J. M., T. A. Bell III, H. M. Alger, J. K. Sawyer, T. L. Smith, K. Kelley, R. Shah, M. D. Wilson, M. A. Davis, R. G. Lee, et al. 2008. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J. Biol. Chem. 283: 10522-10534.
26. Simmonds, W. J., A. F. Hofmann, and E. Theodor. 1967. Absorption of cholesterol from a micellar solution: intestinal perfusion studies in man. J. Clin. Invest. 46: 874-890.
27. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 ( Suppl ): S189-S194.
28. Robins, S. J., and J. M. Fasulo. 1999. Delineation of a novel hepatic route for the selective transfer of unesterified sterols from high-density lipoproteins to bile: studies using the perfused rat liver. Hepatology. 29: 1541-1548.
29. Briand, F., S. U. Naik, I. Fuki, J. S. Millar, C. Macphee, M. Walker, J. Billheimer, G. Rothblat, and D. J. Rader. 2009. Both the peroxisome proliferator-activated receptor (PPAR) delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal re-absorption of HDL-derived cholesterol. Clin. Transl. Sci. 2: 127.
30. Van Eck, M., M. Hoekstra, R. Out, I. S. Bos, J. K. Kruijt, R. B. Hildebrand, and T. J. Van Berkel. 2008. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J. Lipid Res. 49: 136-146.
31. Chapman, M. J. 2006. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. 111: 893-908.
32. Nijstad, N., T. Gautier, F. Briand, D. J. Rader, and U. J. Tietge. 2011. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 140: 1043-1051.
33. Van der Wulp, M. Y., H. J. Verkade, and A. K. Groen. 2012. Regulation of cholesterol homeostasis. Mol. Cell Endocrinol. Epub ahead of print.